Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editors' pick

03-04-2019 | Mental health | Editorial | Article

Diabetes and dementia: Addressing the needs of an overlooked population

Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity.

Hypoglycemia and technology

This 15-minute case presents the identification of problematic hypoglycemia and the appropriate use and monitoring of different technologies in the context of reducing the occurrence and risk of hypoglycemia.

03-18-2019 | Dapagliflozin | Highlight | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

Conference coverage | Diabetes UK Professional Conference 2019

Visit the DUKPC conference hub for all of the coverage, including session reports, video interviews, and more.

Latest from across the site

03-20-2019 | Peripheral arterial disease | News

DECLARE-TIMI 58 outcomes consistent in people with peripheral artery disease

Patients with type 2 diabetes and peripheral artery disease may derive greater absolute benefit from dapagliflozin than those without the comorbidity due to their increased risk for cardiovascular and renal events, DECLARE-TIMI 58 data show.

03-19-2019 | Glycemic control | News

Benefits of full target monitoring shown in type 2 diabetes

Full monitoring of biomedical and lifestyle-related diabetes target indicators is associated with significantly lower glycated hemoglobin levels than incomplete monitoring among people with type 2 diabetes in a care group setting, say researchers.

03-18-2019 | Dapagliflozin | Highlight | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

03-17-2019 | Canagliflozin | News

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

03-15-2019 | Medication adherence | News

Targeted insulin-adherence intervention may improve glycemic control

Targeting specific populations of individuals with type 2 diabetes for intensive interventions to optimize their insulin use may result in better glycemic control than an untargeted approach, findings from the TARGIT-Diabetes trial suggest.

03-14-2019 | Hypoglycemia | News

Real-world hypoglycemia data support continued sulfonylurea role in type 2 diabetes

Hypoglycemia is common among people being treated for type 2 diabetes, particularly those using insulin or a sulfonylurea, but the risk for severe episodes is only elevated among insulin users, suggest results of a prospective UK study.

Meet our Editorial Board

New Content Item Meet our Advisory Board

Latest from us on Twitter

Trending this week

image credits